Massachusetts Financial Services
CYTK icon

Massachusetts Financial Services’s Cytokinetics CYTK Stock Holding History

Massachusetts Financial Services’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.8M Buy
549,348
+237,699
+76% +$17.1M 0.01% 504
2026
Q1 		$20.5M Sell
311,649
-15,553
-5% -$988K 0.01% 639
2025
Q4 		$20.8M Sell
327,202
-169,471
-34% -$10.5M 0.01% 639
2025
Q3 		$27.3M Sell
496,673
-929
-0.2% -$38.3K 0.01% 585
2025
Q2 		$16.4M Buy
497,602
+178,069
+56% +$6.19M 0.01% 641
2025
Q1 		$12.8M Buy
319,533
+252
+0.1% +$11.6K ﹤0.01% 641
2024
Q4 		$15M Sell
319,281
-25,167
-7% -$1.31M ﹤0.01% 631
2024
Q3 		$18.2M Buy
344,448
+68,381
+25% +$3.81M 0.01% 604
2024
Q2 		$15M Buy
+276,067
New +$16.7M ﹤0.01% 607

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Massachusetts Financial Services's CYTK Position: Q2 2026 in Review

Massachusetts Financial Services increased its Cytokinetics (CYTK) stake by 76% in Q2 2026, buying an estimated $17.1M and bringing the position to 549,348 shares worth $46.8M. The position accounts for 0.01% of the portfolio, ranked #504.

Massachusetts Financial Services first reported a position in CYTK in Q2 2024 and has held it in 9 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Massachusetts Financial Services held 549,348 shares of Cytokinetics worth $46.8M as of Q2 2026.
  • Massachusetts Financial Services bought 237,699 Cytokinetics shares in Q2 2026, an estimated $17.1M.
  • Cytokinetics made up 0.01% of Massachusetts Financial Services's portfolio in Q2 2026, its #504 holding.
  • Massachusetts Financial Services first reported a position in Cytokinetics in Q2 2024 and has held it in 9 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Massachusetts Financial Services's 13F filing for Q2 2026, filed 3 Aug 2026.